Department of Surgery, School of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Int J Gynaecol Obstet. 2023 May;161(2):544-551. doi: 10.1002/ijgo.14552. Epub 2022 Nov 21.
To assess and compare circulating tissue inhibitor of metalloproteinase 3 (TIMP-3) concentrations between women with pre-eclampsia and healthy pregnant women. We also aimed to determine the relationships between circulating TIMP-3 and matrix metalloproteinase 2 (MMP-2), MMP-9, TIMP-1, and TIMP-2 concentrations in pre-eclampsia.
A primary case-control study included patients with pre-eclampsia (n = 219) and gestational hypertension (n = 118), healthy pregnant women (n = 214), and non-pregnant women (n = 66), and a replication case-control study included patients with pre-eclampsia (n = 177) and healthy pregnant women (n = 124), all from southeastern Brazil. Plasma TIMP-3, MMP-2, MMP-9, TIMP-1, and TIMP-2 concentrations were assessed using commercially available enzyme-linked immunosorbent assay kits, and the relationships between them were analyzed using Spearman's correlation.
In our primary study, patients with pre-eclampsia and gestational hypertension exhibited increased TIMP-3 concentrations compared with healthy pregnant women (both P < 0.0001) and non-pregnant women (both P < 0.001). These findings were confirmed in the replication study, showing elevated TIMP-3 concentrations in women with pre-eclampsia versus healthy pregnant women (P < 0.001). We found no difference in TIMP-3 concentrations between early-onset and late-onset pre-eclampsia. Moreover, TIMP-3 concentrations were significantly correlated with plasma concentrations of TIMP-1 (r = 0.2333; P = 0.0086) and MMP-2 (r = 0.2159; P = 0.0156) in pre-eclampsia.
Circulating TIMP-3 concentration is increased in women with pre-eclampsia compared with healthy pregnant women, and it is positively correlated with plasma MMP-2 and TIMP-1 concentrations in pre-eclampsia.
评估和比较先兆子痫患者与健康孕妇的循环组织金属蛋白酶抑制剂 3（TIMP-3）浓度。我们还旨在确定先兆子痫患者中循环 TIMP-3 与基质金属蛋白酶 2（MMP-2）、MMP-9、TIMP-1 和 TIMP-2 浓度之间的关系。
一项初步的病例对照研究纳入了来自巴西东南部的先兆子痫患者（n=219）、妊娠期高血压患者（n=118）、健康孕妇（n=214）和非孕妇（n=66），一项复制病例对照研究纳入了先兆子痫患者（n=177）和健康孕妇（n=124）。使用商业可得的酶联免疫吸附测定试剂盒评估血浆 TIMP-3、MMP-2、MMP-9、TIMP-1 和 TIMP-2 浓度，并使用 Spearman 相关分析分析它们之间的关系。
在我们的初步研究中，与健康孕妇（均 P<0.0001）和非孕妇（均 P<0.001）相比，先兆子痫和妊娠期高血压患者的 TIMP-3 浓度升高。在复制研究中也得到了同样的结果，与健康孕妇相比，先兆子痫患者的 TIMP-3 浓度升高（P<0.001）。我们没有发现早发型和晚发型先兆子痫患者之间 TIMP-3 浓度的差异。此外，在先兆子痫患者中，TIMP-3 浓度与血浆 TIMP-1 浓度（r=0.2333；P=0.0086）和 MMP-2 浓度（r=0.2159；P=0.0156）呈显著正相关。
与健康孕妇相比，先兆子痫患者的循环 TIMP-3 浓度升高，并且与先兆子痫患者的血浆 MMP-2 和 TIMP-1 浓度呈正相关。
